Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Liwei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8304-3115; OpenAlex author ID A5100406720. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 4 papers · 2021: 2 papers · 2022: 6 papers · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 3 papers

Papers 27

  1. Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Last author DOI 10.1016/j.canlet.2026.218684↗
  2. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  3. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRAS G12D-mutant pancreatic cancer: a phase 1b/2 trial. Last author DOI 10.1038/s41591-026-04538-9↗
  4. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  5. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma… Last author DOI 10.1038/s41392-024-01948-4↗
  6. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44321-024-00060-y↗
  7. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Last author DOI 10.1016/j.canlet.2023.216095↗
  8. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Last author DOI 10.1016/j.canlet.2023.216206↗
  9. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Last author DOI 10.1002/cac2.12238↗
  10. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Last author DOI 10.1016/j.ebiom.2022.103897↗
  11. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02133-5↗
  12. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Last author DOI 10.1155/2022/5634887↗
  13. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Last author DOI 10.1186/s12935-022-02807-4↗
  14. Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. Last author DOI 10.18632/aging.204031↗
  15. Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer. Co-author DOI 10.4103/jcrt.jcrt_1663_20↗
  16. CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. Last author DOI 10.7150/jca.54482↗
  17. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. Last author DOI 10.1007/s12032-020-01384-8↗
  18. Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-20-0111↗
  19. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. Co-author DOI 10.1186/s13046-019-1489-0↗
  20. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2019.0427↗
  21. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Co-author DOI 10.1158/1541-7786.mcr-18-0910↗
  22. Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer. Last author DOI 10.21037/cco.2019.02.04↗
  23. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. Last author PMID 30899402↗
  24. Synergistic effects of the combination of 5-Aza‑CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Last author DOI 10.3892/or.2017.6059↗
  25. Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-015-3123-x↗
  26. Functional significance of macrophages in pancreatic cancer biology. Last author DOI 10.1007/s13277-015-4127-2↗
  27. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Last author DOI 10.3892/or.2014.3518↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 18 shared papers, 2019–2026 · strength 2.76
  2. Xiaofei Zhang · 8 shared papers, 2021–2023 · strength 1.08
  3. Tiebo Mao · 8 shared papers, 2021–2023 · strength 1.08
  4. Feng Jiao · 10 shared papers, 2014–2022 · strength 0.98
  5. Shengbai Xue · 5 shared papers, 2022–2026 · strength 0.91
  6. Weiyu Ge · 6 shared papers, 2022–2023 · strength 0.82
  7. Shumin Li · 4 shared papers, 2022–2023 · strength 0.55
  8. Jiayu Yao · 4 shared papers, 2022 · strength 0.48
  9. Ming Quan · 4 shared papers, 2019–2023 · strength 0.47
  10. Yanling Wang · 2 shared papers, 2022–2026 · strength 0.46
  11. Ting Han · 4 shared papers, 2015–2020 · strength 0.40
  12. Kuirong Jiang · 2 shared papers, 2024–2026 · strength 0.40
  13. Yongwei Sun · 3 shared papers, 2022–2024 · strength 0.39
  14. Yuexiang Wang · 3 shared papers, 2022–2024 · strength 0.38
  15. Shukui Qin · 2 shared papers, 2024–2026 · strength 0.37
  16. Jiong Hu · 3 shared papers, 2020–2022 · strength 0.34
  17. Meng Zhuo · 3 shared papers, 2018–2020 · strength 0.33
  18. Haiyan Yang · 3 shared papers, 2019–2020 · strength 0.32
  19. Xiao Zhang · 2 shared papers, 2021–2022 · strength 0.29
  20. Hai Xia Hu · 3 shared papers, 2015–2019 · strength 0.28
  21. Yu Wang · 2 shared papers, 2019–2022 · strength 0.27
  22. Kuirong Jiang · 1 shared paper, 2026 · strength 0.24
  23. Wei Li · 1 shared paper, 2026 · strength 0.23
  24. Chunyi Hao · 1 shared paper, 2026 · strength 0.23
  25. Haitao Zhang · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.